{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:58:39Z","timestamp":1793649519440,"version":"4.5.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["954798"],"award-info":[{"award-number":["954798"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030699","name":"Universidad Cat\u00f3lica de Manizales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU17\/03075"],"award-info":[{"award-number":["FPU17\/03075"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115661","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:00:00Z","timestamp":1696993200000},"page":"115661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors"],"prefix":"10.1016","volume":"168","author":[{"given":"M.","family":"Sanz-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Manzano-Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vega-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gonz\u00e1lez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gil-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Somoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pizzamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ar\u00e1nguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Fern\u00e1ndez-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115661_bib1","unstructured":"World Health Organization. Mortality and global health estimates: Causes of death; Projections for 2015\u20132030; Projection of death rates. Available online: http:\/\/apps.who.int\/gho\/data\/node.main.PROJRATEWORLD?lang=en (accessed on September 13th, 2022)."},{"issue":"10302","key":"10.1016\/j.biopha.2023.115661_bib2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet (Lond., Engl. )"},{"issue":"10","key":"10.1016\/j.biopha.2023.115661_bib3","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"11","key":"10.1016\/j.biopha.2023.115661_bib4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2023.115661_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/j.ajkd.2016.11.018","article-title":"Diabetes control and the risks of ESRD and mortality in patients with CKD","volume":"70","author":"Navaneethan","year":"2017","journal-title":"Am. J. Kidney Dis.: Off. J. Natl. Kidney Found."},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10157-012-0646-y","article-title":"Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease","volume":"16","author":"Satoh","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/hy0102.100540","article-title":"Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency","volume":"39","author":"Vaziri","year":"2002","journal-title":"Hypertens. (Dallas, Tex.: 1979)"},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20150517","article-title":"Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria","volume":"130","author":"Pulido-Olmo","year":"2016","journal-title":"Clin. Sci. (Lond., Engl.: 1979)"},{"issue":"10","key":"10.1016\/j.biopha.2023.115661_bib9","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/HJH.0000000000000292","article-title":"Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression","volume":"32","author":"Ruiz-Hurtado","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2023.115661_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2369-13-37","article-title":"Association between microalbuminuria and subclinical atherosclerosis evaluated by carotid artery intima-media in elderly patients with normal renal function","volume":"13","author":"Kong","year":"2012","journal-title":"BMC Nephrol."},{"issue":"17","key":"10.1016\/j.biopha.2023.115661_bib11","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1111\/bph.13223","article-title":"Genetic predisposition to albuminuria is associated with increased arterial stiffness: role of elastin","volume":"172","author":"Gil-Ortega","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone reduces intrinsic arterial stiffness in munich wistar fr\u00f6mter rats, a genetic model of chronic kidney disease","volume":"51","author":"Gil-Ortega","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115661_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.644","article-title":"The emerging role of phosphate in vascular calcification","volume":"75","author":"Giachelli","year":"2009","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","article-title":"Arterial stiffening and vascular calcifications in end-stage renal disease","volume":"15","author":"Gu\u00e9rin","year":"2000","journal-title":"Nephrol., Dial., Transplant.: Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"2","key":"10.1016\/j.biopha.2023.115661_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1523-1755.2001.060002472.x","article-title":"Pathophysiological mechanisms of vascular calcification in end-stage renal disease","volume":"60","author":"Davies","year":"2001","journal-title":"Kidney Int."},{"issue":"18","key":"10.1016\/j.biopha.2023.115661_bib16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.99.18.2434","article-title":"Impact of aortic stiffness on survival in end-stage renal disease","volume":"99","author":"Blacher","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1681\/ASN.2019020117","article-title":"Arterial Stiffness in the Heart Disease of CKD","volume":"30","author":"Zanoli","year":"2019","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijms24010040","article-title":"Imbalance in bone morphogenic proteins 2 and 7 is associated with renal and cardiovascular damage in chronic kidney disease","volume":"24","author":"Manzano-Lista","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.115661_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2010.04.023","article-title":"Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease","volume":"211","author":"Dalfino","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib20","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1159\/000366400","article-title":"Vascular calcification in chronic kidney disease is induced by bone morphogenetic protein-2 via a mechanism involving the Wnt\/\u03b2-catenin pathway","volume":"34","author":"Rong","year":"2014","journal-title":"Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol., Biochem., Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1172\/JCI2237","article-title":"Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat","volume":"102","author":"Vukicevic","year":"1998","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib22","doi-asserted-by":"crossref","first-page":"F130","DOI":"10.1152\/ajprenal.2000.279.1.F130","article-title":"Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction","volume":"279","author":"Hruska","year":"2000","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2337\/db06-1226","article-title":"Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors","volume":"56","author":"Sugimoto","year":"2007","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2023.115661_bib24","doi-asserted-by":"crossref","first-page":"F1006","DOI":"10.1152\/ajprenal.00382.2002","article-title":"BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells","volume":"284","author":"Wang","year":"2003","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2023.115661_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vph.2018.02.004","article-title":"Renal perivascular adipose tissue: form and function","volume":"106","author":"Restini","year":"2018","journal-title":"Vasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115661_bib26","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/db20-1031","article-title":"Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2023.115661_bib27","doi-asserted-by":"crossref","first-page":"6076145","DOI":"10.1155\/2020\/6076145","article-title":"The relationship between perirenal fat thickness and reduced glomerular filtration rate in patients with type 2 diabetes","volume":"2020","author":"Fang","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"10","key":"10.1016\/j.biopha.2023.115661_bib28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/jch.13366","article-title":"Para-perirenal distribution of body fat is associated with reduced glomerular filtration rate regardless of other indices of adiposity in hypertensive patients","volume":"20","author":"Geraci","year":"2018","journal-title":"J. Clin. Hypertens. (Greenwich, Conn. )"},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/0003319718799967","article-title":"Perirenal fat: a unique fat pad and potential target for cardiovascular disease","volume":"70","author":"Liu","year":"2019","journal-title":"Angiology"},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.orcp.2020.06.006","article-title":"Peri-renal fat thickness is positively associated with the urine albumin excretion rate in patients with type 2 diabetes","volume":"14","author":"Shen","year":"2020","journal-title":"Obes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2023.115661_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"31","key":"10.1016\/j.biopha.2023.115661_bib33","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.biopha.2023.115661_bib34","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"24","key":"10.1016\/j.biopha.2023.115661_bib35","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115661_bib37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1152\/physiolgenomics.00008.2015","article-title":"Development of progressive albuminuria in male Munich Wistar Fr\u00f6mter rats is androgen dependent","volume":"47","author":"Herlan","year":"2015","journal-title":"Physiol. Genom."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib39","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115661_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/biomedicines10030610","article-title":"Neural network-based calculator for rat glomerular filtration rate","volume":"10","author":"Pellicer-Valero","year":"2022","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.biopha.2023.115661_bib41","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1097\/HJH.0b013e3283642384","article-title":"Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model","volume":"31","author":"Steireif","year":"2013","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.hjh.0000163145.12707.63","article-title":"Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses","volume":"23","author":"Alvarez","year":"2005","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.biopha.2023.115661_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/bjp.2008.110","article-title":"Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats","volume":"154","author":"Shi","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3803\/EnM.2021.1296","article-title":"Cardiovascular outcomes with finerenone according to glycemic status at baseline and prior treatment with newer antidiabetics among patients with type 2 diabetes mellitus","volume":"37","author":"Patoulias","year":"2022","journal-title":"Endocrinol. Metab. (Seoul., Korea)"},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib45","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes care"},{"issue":"12","key":"10.1016\/j.biopha.2023.115661_bib46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115661_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cytogfr.2011.08.001","article-title":"Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency","volume":"22","author":"Boon","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.biopha.2023.115661_bib48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/ki.2012.383","article-title":"Circulating bone morphogenetic protein-7 and transforming growth factor-\u03b21 are better predictors of renal end points in patients with type 2 diabetes mellitus","volume":"83","author":"Wong","year":"2013","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.biopha.2023.115661_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050593","article-title":"Increased cyclooxygenase-2-derived prostanoids contributes to the hyperreactivity to noradrenaline in mesenteric resistance arteries from offspring of diabetic rats","volume":"7","author":"Ramos-Alves","year":"2012","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.biopha.2023.115661_bib50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MOL.0b013e32830c91e3","article-title":"Differential vascular functions of Nox family NADPH oxidases","volume":"19","author":"Brandes","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115661_bib51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00109-009-0544-2","article-title":"Translating the oxidative stress hypothesis into the clinic: NOX versus NOS","volume":"87","author":"Armitage","year":"2009","journal-title":"J. Mol. Med. (Berl., Ger. )"},{"issue":"8","key":"10.1016\/j.biopha.2023.115661_bib52","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2337\/diabetes.51.8.2648","article-title":"Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin","volume":"51","author":"Christ","year":"2002","journal-title":"Diabetes"},{"issue":"22","key":"10.1016\/j.biopha.2023.115661_bib53","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehv564","article-title":"NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice","volume":"37","author":"Langbein","year":"2016","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115661_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/j.2040-4603.2018.tb00004.x","article-title":"Role of perivascular adipose tissue in health and disease","volume":"8","author":"Fern\u00e1ndez-Alfonso","year":"2017","journal-title":"Compr. Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tem.2015.04.003","article-title":"Regional differences in perivascular adipose tissue impacting vascular homeostasis","volume":"26","author":"Gil-Ortega","year":"2015","journal-title":"Trends Endocrinol. Metab.: TEM"},{"issue":"3","key":"10.1016\/j.biopha.2023.115661_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfq522","article-title":"Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients","volume":"26","author":"Lamacchia","year":"2011","journal-title":"Nephrol., Dial., Transplant.: Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib58","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s11255-013-0404-4","article-title":"Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients","volume":"45","author":"Sun","year":"2013","journal-title":"Int. Urol. Nephrol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115661_bib59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am. J. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115661_bib60","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.biopha.2023.115661_bib61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:10:11Z","timestamp":1779916211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223014592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":61,"alternative-id":["S0753332223014592"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115661","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115661"}}